长期聚焦帕金森病临床及基础研究、慢病长程管理，”荣获亚太MDS-AOS 2019 AOPMC年会Blue Ribbon Highlight奖。共发表SCI文章141篇，论文共被引用4400多次，H指数39(Google Scholar)。2020年以来以（共）通讯/第一作者发表SCI研究成果42篇，包括Brain(2), JAMA Neurol, Cell Res, Nat Commun, Mov Disord(6), JNM, EJNMMI, NPJ Parkinsons Dis(2). 主持重大(培育)、面上、青年等国自然基金共8项，主持科技部国家重点研发计划“重大慢性非传染性疾病防控研究”重点专项“帕金森病分子影像学研究”、 国家卫健委国家临床重点专科建设项目-功能神经疾病智能综合管理和诊疗体系建设、及多项省部级课题。 2020年以来发表的代表作： 1. Shen Y#, Yu WB#, Shen B#, ... Koprich JB*, Huang ZL*, Wang J*. Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice. Brain 2020. 143:3374-3392.   2. Tian M*, Zuo C*, Cahid Civelek A*, ... Zhang H*, Wang J*, Molecular Imaging-based Precision Medicine Task Group of AFP: International consensus on clinical use of presynaptic dopaminergic positron emission tomography imaging in parkinsonism. Eur J Nucl Med Mol Imaging 2023. DOI: 10.1007/s00259-023-06403-0 3. Liu FT#, Lu JY#, Li XY#, ..., Zuo C*, Wang J*, Progressive Supranuclear Palsy Neuroimage I: (18) F-Florzolotau Positron Emission Tomography Imaging of Tau Pathology in the Living Brains of Patients with Corticobasal Syndrome. Mov Disord 2023. 2023-04-01;38(4):579-588. 4. Tang Y#, Han L#, Li S#, ..., Wu J, Wang J*: Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia. NPJ Parkinsons Dis 2023, 2023-02-09;9(1):23. 5. Sun YM#, Zhou XY#, Liang XN#, Lin JR#, ... An Y*, Wu JJ*, Wang J*: The genetic spectrum of a cohort of patients clinically diagnosed as Parkinson's disease in mainland China. NPJ Parkinsons Dis 2023, 9:76. 6. Liu FT#, Lu JY#, Li XY#, ... Zuo CT*, Wang J*. 18F‐Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy. EUR J NUCL MED MOL I.  2023-04-01;50(5):1395-1405.   7. Tang YL#, Li L#, Hu TY#, Jiao FY, Han LL, Li SY, Xu ZH, Fan Y, Sun YM, Liu FT, MD, Yen TC, Zuo CT*, Wang J*.  In Vivo 18F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson’s Disease Dementia. Mov Disord 2023-01-01;38(1):147-152.   8. Zhou XY#, Lu JY#, Liu FT, Wu P, Zhao J, Ju ZZ, Tang YL, Shi QY, Lin HM, Wu JJ, Yen TC, Zuo CT*, Sun YM*, Wang J*. In Vivo 18F‐APN-1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings.  Mov Disord 2022, 37:525-534. 9. Liu FT#, Li XY#, ... Zuo CT*, Wang J*. 18F-Florzolotau tau PET imaging in patients with multiple system atrophy-Parkinsonian type. Mov Disord. 2022. 37(9):1915-1923. 10. Fan Y#, Zhao Q#, ..., Liu C*, Wang J*, Li D*. Generic amyloid fibrillation of TMEM106B in patient with Parkinson's disease dementia and normal elders. Cell Res 2022,0:1-4. 10.1038/s41422-022-00665-3.   11. Wu P#, Zhao Y#, ..., Wang J*, Zuo C*, Shi K. Differential diagnosis of parkinsonism based on deep metabolic imaging indices. J Nucl Med 2022. J Nucl Med 2022, 2022-11-01; 63(11):1741-1747.  IF: 11.802 12. Li L#, Liu FT#, ... Wang J*, Zuo CT*, and the Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). Clinical utility of 18F-APN-1607 tau PET imaging in patients with progressive supranuclear palsy. Mov Disord 2021,36:2314-2323   13. Sun YM#,  Yu HL#,  ..., An Y*, Wu JJ*, Wang J*. Disease Progression in Patients with Parkin-related Parkinson's Disease in a Longitudinal Cohort.  Mov Disord 2021;36:442-448. 14. Liu FT, Wang J*, Chen Y*: Lost Dopaminergic Bindings in the Caudate of a Patient With Frontotemporal Lobar Degeneration-Motor Neuron Disease. JAMA Neurol 2020, 77:1448-1449.   15. Guo M#, Wang J#, Zhao Y, Feng Y, Han S, Dong Q*, Cui M*, Tieu K: Microglial exosomes facilitate alpha-synuclein transmission in Parkinson's disease. Brain 2020. 143:1476-1497.   16. Lou MM, Tang XQ, Wang GM, ..., Wang J*, Xu J*, and Wang WY*.  Long noncoding RNA BS-DRL1 modulates the DNA damage response and genome stability by interacting with HMGB1 in neurons. Nat Commun 2021, 12: 4075-4092.